Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GenKyoTex, PsiOxus Raise VC Funding In Europe To Reach Phase II POC

This article was originally published in The Pink Sheet Daily

Executive Summary

GenKyoTex's first-in-class NOX inhibitors and PsiOxus's oncolytic viruses attract funding from European VCs to cross "death valley."

You may also be interested in...



Start-Up Quarterly Statistics, Q3 2012

In the third quarter of 2012, start-up companies raised a total of $682 million across all industries, roughly 19% more than in the previous quarter. Of that money, 65% went to biopharmas. Several large molecule-focused companies inked deals during Q3. Four start-ups were acquired – three biopharmas and one medical device company.

Financings Of The Fortnight: Secondary Offerings Up From Pace Set In 2010 And 2011

Plus news on recent financings by Genkyotex, Synageva, Nektar Therapeutics and Edmond de Rothschild Investment Partners.

Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal

Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074483

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel